[1] Lei YY, Yang JJ, Zhong WZ, et al. Clinical efficacy of crizotinib in Chinese patients with ALKpositive nonsmallcell lung cancer with brain metastases[J]. J Thorac Dis, 2015, 7(7): 1181-1188. DOI:10.3978/j.issn.20721439.2015.06.04.
[2] Pikor LA, Ramnarine VR, Lam S, et al. Genetic alterations defining NSCLC subtypes and their therapeutic implications[J]. Lung Cancer, 2013, 82(2): 179-189. DOI: 10.1016/j.lungcan.2013.07.025.
[3] Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology[J]. Nat Rev Cancer, 2013, 13(10): 685-700. DOI: 10.1038/nrc3580.
[4] Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALKrearranged nonsmallcell lung cancer[J]. N Engl J Med, 2014, 370(13): 1189-1197. DOI: 10.1056/NEJMoa1311107.
[5] Wong DW, Leung EL, Wong SK, et al. A novel KIF5BALK variant in nonsmall cell lung cancer[J]. Cancer, 2011, 117(12): 2709-2718. DOI: 10.1002/cncr.25843.
[6] Lawrence K, Berry B, Handshoe J, et al. Detection of a TRAF1ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitorresistant disease[J]. BMC Res Notes, 2015, 8(8): 308. DOI: 10.1186/s1310401512777.
[7] Teixidó C, Karachaliou N, Peg V, et al. Concordance of IHC, FISH and RTPCR for EML4ALK rearrangements[J]. Transl Lung Cancer Res, 2014, 3(2): 70-74. DOI: 10.3978/j.issn.22186751.2014.02.02.
[8] Shen Q, Wang X, Yu B, et al. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALKrearranged nonsmall cell lung cancer (NSCLC)[J]. Lung Cancer, 2015, 90(3): 492-498. DOI: 10.1016/j.lungcan.2015.10.002. |